Trial Profile

An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CX 801 (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Malignant melanoma; Renal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors CytomX Therapeutics

Most Recent Events

08 Jan 2026 According to a CytomX Therapeutics media release, the initial clinical data for CX801 in combination with KEYTRUDA in advanced melanoma is anticipated by the end of 2026.
08 Jan 2026 According to a CytomX Therapeutics media release, study of CX-801 monotherapy dose escalation has reached the fourth dose level.
06 Nov 2025 According to a CytomX Therapeutics media release, study currently enrolling the 2nd dose level.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com